225 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Purchased by Magnolia Capital Advisors LLC

Magnolia Capital Advisors LLC purchased a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 225 shares of the biopharmaceutical company’s stock, valued at approximately $236,000.

Other institutional investors also recently bought and sold shares of the company. West Paces Advisors Inc. raised its stake in Regeneron Pharmaceuticals by 575.0% in the first quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 23 shares in the last quarter. Stephens Consulting LLC bought a new position in Regeneron Pharmaceuticals in the second quarter worth about $26,000. Sachetta LLC grew its holdings in Regeneron Pharmaceuticals by 71.4% in the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 10 shares during the period. Crewe Advisors LLC purchased a new stake in Regeneron Pharmaceuticals in the first quarter worth about $28,000. Finally, Lynx Investment Advisory purchased a new stake in Regeneron Pharmaceuticals in the second quarter worth about $33,000. 83.31% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on REGN. Guggenheim upped their price objective on shares of Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. Canaccord Genuity Group restated a “buy” rating and issued a $1,152.00 price objective on shares of Regeneron Pharmaceuticals in a report on Thursday, June 27th. JPMorgan Chase & Co. upped their price objective on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. Truist Financial restated a “buy” rating and issued a $1,200.00 price objective on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 24th. Finally, Morgan Stanley cut their price target on shares of Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating on the stock in a report on Thursday, July 11th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $1,118.62.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the transaction, the chief financial officer now directly owns 15,305 shares in the company, valued at $18,447,575.65. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the transaction, the chief financial officer now directly owns 15,305 shares in the company, valued at $18,447,575.65. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Joseph J. Larosa sold 1,866 shares of the stock in a transaction that occurred on Thursday, July 11th. The stock was sold at an average price of $1,088.95, for a total transaction of $2,031,980.70. Following the completion of the transaction, the executive vice president now owns 37,937 shares in the company, valued at $41,311,496.15. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 8,033 shares of company stock worth $9,399,345. Company insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 0.8 %

Shares of Regeneron Pharmaceuticals stock opened at $1,051.24 on Tuesday. The company has a market cap of $115.83 billion, a price-to-earnings ratio of 31.06, a price-to-earnings-growth ratio of 3.57 and a beta of 0.12. The company’s 50 day moving average is $1,128.54 and its 200 day moving average is $1,036.16. Regeneron Pharmaceuticals, Inc. has a twelve month low of $769.19 and a twelve month high of $1,211.20. The company has a quick ratio of 4.62, a current ratio of 5.44 and a debt-to-equity ratio of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, beating analysts’ consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The company had revenue of $3.55 billion for the quarter, compared to the consensus estimate of $3.38 billion. During the same quarter in the prior year, the firm earned $8.79 earnings per share. The firm’s revenue for the quarter was up 12.3% compared to the same quarter last year. Research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.8 EPS for the current year.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.